So on a day with progress on the new CMO and on new '335 trial front, CORT keeps pushing on getting more patents to defend against generic Mife.
IMHO keep your eye on those applications that are directly related to the Cushing's FDA label and are "non-diagnostic" or titration (we got 5 of those granted and more on way).
Thus most significant one is dosing with food / optimizing absorption ('465 app) and the second one for combo with CYP3A drugs ('368). Corcept has one granted CYP3A patent that is part of the current Teva litigation, but this second one has to some extant broader / stronger claims and would further support the position.
On both these apps ('465 & '368) Corcept has filed amended claims last week and argument for grant of the patent after interview with examiner. Corcept seems to address the examiner's objections but IMHO it is a coin-toss. Should one of these two additional non-diagnostic patents come through expect that there will be a new complaint and new case against Teva.